{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:52:56Z","timestamp":1784155976911,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jconrel.2023.04.004","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T17:55:03Z","timestamp":1680803703000},"page":"310-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Guanidine-modified nanoparticles as robust BTZ delivery carriers and activators of immune responses"],"prefix":"10.1016","volume":"357","author":[{"given":"Xiaodan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuxian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youqing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.04.004_bb0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","article-title":"Cancer nanomedicine for combination cancer immunotherapy","volume":"4","author":"Nam","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0010","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41401-020-0448-9","article-title":"Cancer nanomedicine meets immunotherapy: opportunities and challenges","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges","volume":"17","author":"Martin","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0025","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.apsb.2020.08.010","article-title":"Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy","volume":"10","author":"Zhu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0030","doi-asserted-by":"crossref","first-page":"62607","DOI":"10.18632\/oncotarget.11546","article-title":"Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.617335","article-title":"Progress and challenges of predictive biomarkers for immune checkpoint blockade","volume":"11","author":"Lei","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0045","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41577-019-0271-z","article-title":"Immune crosstalk in cancer progression and metastatic spread: a complex conversation","volume":"20","author":"Garner","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0050","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0055","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1038\/s41467-020-19970-9","article-title":"Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death","volume":"11","author":"Hayashi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0060","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/cancers12041047","article-title":"Current approaches for combination therapy of cancer: the role of immunogenic cell death","volume":"12","author":"Asadzadeh","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0065","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3390\/cells11091415","article-title":"Immunogenic cell death, DAMPs and prothymosin \u03b1 as a putative anticancer immune response biomarker","volume":"11","author":"Birmpilis","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0075","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119649","article-title":"Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses","volume":"230","author":"Liu","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0085","doi-asserted-by":"crossref","first-page":"27536","DOI":"10.1021\/acsami.9b07804","article-title":"Effective radiotherapy in tumor assisted by ganoderma iucidum polysaccharide-conjugated bismuth sulfide nanoparticles through radiosensitization and dendritic cell activation","volume":"11","author":"Yu","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0090","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1021\/acs.nanolett.1c00977","article-title":"Cooperative self-assembled nanoparticle induces sequential immunogenic cell death and toll-like receptor activation for synergistic chemo-immunotherapy","volume":"21","author":"Wang","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0095","doi-asserted-by":"crossref","first-page":"2101897","DOI":"10.1002\/smll.202101897","article-title":"Reinforcing the induction of immunogenic cell death via artificial engineered cascade bioreactor-enhanced chemo-immunotherapy for optimizing cancer immunotherapy","volume":"16","author":"Sun","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0100","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1021\/acsnano.0c03881","article-title":"Nanoenabled disruption of multiple barriers in antigen cross-presentation of dendritic cells via calcium interference for enhanced chemo-immunotherapy","volume":"14","author":"An","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0105","doi-asserted-by":"crossref","first-page":"19355","DOI":"10.1021\/acsami.8b01954","article-title":"Dual pH-responsive shell-cleavable polycarbonate micellar nanoparticles for in vivo anticancer drug delivery","volume":"10","author":"Liu","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0110","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1021\/acs.nanolett.8b03015","article-title":"Foe to friend: supramolecular nanomedicines consisting of natural polyphenols and bortezomib","volume":"18","author":"Wang","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0115","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1039\/C5CC01371B","article-title":"Acid-labile boronate-bridged dextran-bortezomib conjugate with up-regulated hypoxic tumor suppression","volume":"51","author":"Xu","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0120","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1158\/0008-5472.CAN-16-3119","article-title":"Multifunctional telodendrimer nanocarriers restore synergy of bortezomib and doxorubicin in ovarian cancer treatment","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0125","doi-asserted-by":"crossref","first-page":"41003","DOI":"10.1021\/acsami.8b07527","article-title":"A targeted and pH-responsive bortezomib nanomedicine in the treatment of metastatic bone tumors","volume":"10","author":"Wang","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2019.12.043","article-title":"A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways","volume":"319","author":"Huang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jconrel.2019.11.031","article-title":"Photothermally triggered cytosolic drug delivery of glucose functionalized polydopamine nanoparticles in response to tumor microenvironment for the GLUT1-targeting chemo-phototherapy","volume":"317","author":"Li","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/2643-3230.BCD-21-0059","article-title":"Bortezomib induces immunogenic cell death in multiple myeloma","volume":"2","author":"Zitvogel","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0145","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1007\/s12274-021-3314-2","article-title":"High drug loading and pH-responsive nanomedicines driven by dynamic boronate covalent chemistry for potent cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"Nano Res."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0150","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1470-2045(17)30613-7","article-title":"Carfilzomib versus bortezomib: no longer an ENDEAVOR","volume":"18","author":"WCJ Donk","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0155","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/1078155210386268","article-title":"Stability of unused reconstituted bortezomib in original manufacturer vials","volume":"17","author":"Vanderloo","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.31635\/ccschem.020.202000133","article-title":"A ROSs-stimulus-responsive nanocarrier loading with guanidine-modified hydroxycamptothecin prodrug for enhanced antitumor efficacy","volume":"2","author":"Liu","year":"2020","journal-title":"CCS Chem."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0165","doi-asserted-by":"crossref","first-page":"43923","DOI":"10.1021\/acsami.8b17041","article-title":"Detachable polyzwitterion-coated ternary nanoparticles based on peptide dendritic carbon dots for efficient drug delivery in cancer therapy","volume":"10","author":"Ma","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.colsurfa.2015.03.037","article-title":"Application of guanidine-containing polymers for preparation of pH responsive silica-based particles for drug delivery systems","volume":"477","author":"Timin","year":"2015","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0175","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ejmech.2014.06.069","article-title":"Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy","volume":"83","author":"Ma'Mani","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0180","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1021\/ja0482536","article-title":"Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells","volume":"126","author":"Rothbard","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0185","doi-asserted-by":"crossref","first-page":"13413","DOI":"10.1039\/C7NR04470D","article-title":"Engineering biodegradable guanidyl-decorated PEG-PCL nanoparticles as robust exogenous activators of DCs and antigen cross-presentation","volume":"9","author":"Li","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0190","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1039\/C6TB01556E","article-title":"Guanidinylated cationic nanoparticles as robust protein antigen delivery systems and adjuvants for promoting antigen-specific immune responses: in vivo","volume":"4","author":"Li","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2014.12.043","article-title":"Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy","volume":"208","author":"Shen","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.copbio.2020.06.007","article-title":"Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy","volume":"66","author":"Yan","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0205","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2021.07.038","article-title":"Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death","volume":"337","author":"Banstola","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0210","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.638694","article-title":"Japanese encephalitis virus infected human monocyte-derived dendritic cells activate a transcriptional network leading to an antiviral inflammatory response","volume":"12","author":"Chauhan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0220","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jconrel.2022.01.015","article-title":"Codelivery of shikonin and siTGF-\u03b2 for enhanced triple negative breast cancer chemo-immunotherapy","volume":"34","author":"Li","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0225","doi-asserted-by":"crossref","first-page":"13994","DOI":"10.1073\/pnas.1510760112","article-title":"Differential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturation","volume":"112","author":"Hu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.04.004_bb0230","article-title":"Biodegradable zwitterionic polymer membrane coating endowing nanoparticles with ultra-long circulation and enhanced tumor photothermal therapy","volume":"231","author":"Peng","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.04.004_bb0235","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.actbio.2017.10.034","article-title":"Surface-adaptive zwitterionic nanoparticles for prolonged blood circulation time and enhanced cellular uptake in tumor cells","volume":"65","author":"Ou","year":"2017","journal-title":"Acta Biomater."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923002547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923002547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:41:20Z","timestamp":1759164080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923002547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":47,"alternative-id":["S0168365923002547"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guanidine-modified nanoparticles as robust BTZ delivery carriers and activators of immune responses","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}